It's been a miserable past three years for Pfizer (NYSE: PFE) shareholders. Although this drugmaker's stock was all the rage in the early days of the COVID-19 pandemic, as it co-created a coronavirus vaccine as well as supplied a treatment, it's been unable to reproduce those incredible results. 2025's projected top line of between $61 billion and$64 billion remains markedly below 2022's record-breaking peak revenue of just over $100 billion. It would also be naïve to ignore that the pharmaceutical comp ...